PMID: 9449262Feb 4, 1998Paper

Expression of Pseudomonas aeruginosa multidrug efflux pumps MexA-MexB-OprM and MexC-MexD-OprJ in a multidrug-sensitive Escherichia coli strain

Antimicrobial Agents and Chemotherapy
R SrikumarK Poole

Abstract

The mexCD-oprJ and mexAB-oprM operons encode components of two distinct multidrug efflux pumps in Pseudomonas aeruginosa. To assess the contribution of individual components to antibiotic resistance and substrate specificity, these operons and their component genes were cloned and expressed in Escherichia coli. Western immunoblotting confirmed expression of the P. aeruginosa efflux pump components in E. coli strains expressing and deficient in the endogenous multidrug efflux system (AcrAB), although only the delta acrAB strain, KZM120, demonstrated increased resistance to antibiotics in the presence of the P. aeruginosa efflux genes. E. coli KZM120 expressing MexAB-OprM showed increased resistance to quinolones, chloramphenicol, erythromycin, azithromycin, sodium dodecyl sulfate (SDS), crystal violet, novobiocin, and, significantly, several beta-lactams, which is reminiscent of the operation of this pump in P. aeruginosa. This confirmed previous suggestions that MexAB-OprM provides a direct contribution to beta-lactam resistance via the efflux of this group of antibiotics. An increase in antibiotic resistance, however, was not observed when MexAB or OprM alone was expressed in KZM120. Thus, despite the fact that beta-lactams ac...Continue Reading

References

Sep 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·H TowbinJ Gordon
Nov 1, 1991·Molecular & General Genetics : MGG·J R KleinR Plapp
May 5, 1991·Journal of Molecular Biology·F W Studier
Jun 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·C Wandersman, P Delepelaire
Sep 1, 1990·Antimicrobial Agents and Chemotherapy·H FukudaS Iyobe
Jul 1, 1989·Journal of Bacteriology·A Darzins, M J Casadaban
Jan 1, 1985·Antimicrobial Agents and Chemotherapy·F Yoshimura, H Nikaido
Nov 1, 1989·Antimicrobial Agents and Chemotherapy·H Nikaido
Apr 1, 1987·Antimicrobial Agents and Chemotherapy·K HiraiS Mitsuhashi
May 5, 1986·Journal of Molecular Biology·F W Studier, B A Moffatt
Dec 1, 1994·Trends in Microbiology·D MaH Nikaido
Sep 1, 1995·Genetics·L H ZhangR Kolter
Sep 1, 1995·Antimicrobial Agents and Chemotherapy·X Z LiK Poole
Oct 1, 1996·Journal of Bacteriology·H Nikaido
Oct 1, 1996·Antimicrobial Agents and Chemotherapy·T KöhlerJ C Pechere
Apr 1, 1997·Antimicrobial Agents and Chemotherapy·N BiancoK Poole

❮ Previous
Next ❯

Citations

Aug 10, 2000·Molecular Microbiology·H I Zgurskaya, H Nikaido
May 30, 2002·The Journal of Biological Chemistry·Daniel LimNatalie C J Strynadka
Jul 3, 2002·The Journal of Experimental Medicine·Yoichi HirakataDavid P Speert
Nov 12, 2002·Journal of Bacteriology·Elena B TikhonovaHelen I Zgurskaya
Oct 25, 2003·The Journal of Biological Chemistry·Satoshi MurakamiAkihito Yamaguchi
Jun 5, 2007·Journal of Bacteriology·Denis M DaigleKeith Poole
Feb 13, 2008·Antimicrobial Agents and Chemotherapy·Mathieu HernouldCorinne Arpin
Aug 22, 2000·Antimicrobial Agents and Chemotherapy·P M FurneriG Tempera
Aug 22, 2000·Antimicrobial Agents and Chemotherapy·K Poole
Mar 17, 2004·FEMS Microbiology Letters·Florence JudeClaudine Quentin
May 25, 2002·Journal of Bacteriology·Jiangsheng ShenKeith Poole
Jun 19, 2007·Journal of Bacteriology·Matthew B Lawrenz, Virginia L Miller
Dec 1, 2007·Microbiology·Taira MatsuoTeruo Kuroda
Feb 3, 2016·Infection and Immunity·Natasha Weatherspoon-Griffin, Helen J Wing
Jun 7, 2017·Antimicrobial Agents and Chemotherapy·Clayton W HallThien-Fah Mah
Feb 5, 2000·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·S JalalB Wretlind
Jan 14, 2004·Drugs·Xian-Zhi Li, Hiroshi Nikaido
Aug 30, 2005·Antimicrobial Agents and Chemotherapy·Richard J GillisBarbara H Iglewski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.